Abstract Body

Background

Tuberculosis (TB) remains the deadliest infectious disease globally and is the primary cause of death among people with HIV. In 2023, an estimated 1.3 million individuals died from TB, and roughly one-fourth of the global population has been infected with latent TB (LTBI, asymptomatic M. tuberculosis infection). Epigenetics, which influences gene expression through mechanisms such as DNA methylation (DNAm), provides an avenue to study the molecular effects of LTBI. Prior work demonstrated that infectious and non-communicable diseases can lead to accelerated epigenetic aging, a predictor of elevated disease risk and premature death. We hypothesized that individuals with LTBI have accelerated epigenetic aging compared to uninfected individuals.

Methods

We enrolled 75 adult household contacts of people with active pulmonary TB treated at the National Center for Tuberculosis and Lung Disease (Tbilisi, Georgia). Blood samples were collected for QuantiFERON-TB Gold Plus (QFT) testing to determine LTBI status and for DNAm profiling. Epigenetic ages were estimated using the DNA Methylation Age Calculator. Age acceleration was calculated as the difference between DNAm age and chronological age.  We used multiple linear regression models to assess the associations between binary TB infection status or continuous TB antigen responses and epigenetic age acceleration, adjusting for sex.

Results

Among household contacts, 37 were QFT-positive (QFT+) and 38 QFT-negative (QFT-). These groups had a similar distribution of smoking status, hypertension, and body mass index. QFT+ individuals had an average age acceleration of 3.8 years (95%CI 0.7–6.8), 3.2 years (95%CI 0.6–5.8), and 4.2 years (95%CI 0.5–7.9) higher than QFT- individuals on HorvathAge, HannumAge, and PhenoAge, respectively. Each unit increase in QFT TB1 Antigen levels corresponded to a 2.3-year (95%CI 1.3–3.2), 1.7-year (95%CI 0.9–2.6), and 2.2-year (95%CI 1.0–3.4) rise in age acceleration on the three clocks, respectively. QFT TB2 Antigens analyses showed the same direction of effect (0.63, 0.75, and 0.64 years, respectively) but were not statistically significant.

Conclusions

These findings suggest that people with LTBI may experience faster epigenetic aging despite lacking TB clinical symptoms. The results align with prior evidence linking infections and chronic conditions to accelerated epigenetic aging, underscoring the need for global TB prevention interventions, including treatment of LTBI to prevent progression to active TB disease.